Last update Aug. 7, 2019
Likely Compatibility
We do not have alternatives for Элтромбопаг.
Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.
Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.
Thank you for helping to protect and promote breastfeeding.
Элтромбопаг is Eltrombopag in Cyrillic.
Is written in other languages:Элтромбопаг is also known as
Элтромбопаг belongs to this group or family:
Main tradenames from several countries containing Элтромбопаг in its composition:
Variable | Value | Unit |
---|---|---|
Oral Bioavail. | 52 | % |
Molecular weight | 443 | daltons |
Protein Binding | 99.9 | % |
pKa | 3.99 | - |
Tmax | 2 - 6 | hours |
T½ | 26 - 35 | hours |
Write us at elactancia.org@gmail.com
e-lactancia is a resource recommended by IHAN of Spain
Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM
A thrombopoietin receptor agonist that increases platelet production. Indicated in the treatment of immune thrombopenic purpura, severe aplastic anemia and hepatitis C.
Administered orally once a day.
Since the last update we have not found published data on its excretion in breastmilk.
Its pharmacokinetic data (high percentage of protein binding and very low pKa) makes transfer to milk in significant amounts unlikely.
Its low oral bioavailability impedes transfer from breastmilk to infant plasma, except in premature infants and the immediate neonatal period when there may be greater intestinal permeability.
In addition, eltrombopag forms chelates with polyvalent ions such as calcium, which significantly reduces the drug’s possible absorption by the infant (EMA 2015)
Its use is authorized in Pediatrics from one year of age (EMA 2015).